These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34528900)

  • 1. Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells.
    Tortelli TC; Tamura RE; de Souza Junqueira M; da Silva Mororó J; Bustos SO; Natalino RJM; Russell S; Désaubry L; Strauss BE; Chammas R
    Aging (Albany NY); 2021 Sep; 13(18):21914-21940. PubMed ID: 34528900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
    Kuo KT; Huang WC; Bamodu OA; Lee WH; Wang CH; Hsiao M; Wang LS; Yeh CT
    Clin Epigenetics; 2018 Aug; 10(1):107. PubMed ID: 30092824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
    Shen X; Zhuang Z; Zhang Y; Chen Z; Shen L; Pu W; Chen L; Xu Z
    Tumour Biol; 2015 Sep; 36(9):7133-42. PubMed ID: 25877751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.
    Duarte ML; de Moraes E; Pontes E; Schluckebier L; de Moraes JL; Hainaut P; Ferreira CG
    Cancer Lett; 2009 Jun; 279(1):57-64. PubMed ID: 19217709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
    Duan L; Perez RE; Calhoun S; Maki CG
    Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
    Hu Z; Zeng Q; Zhang B; Liu H; Wang W
    Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities.
    Riaz MA; Sak A; Erol YB; Groneberg M; Thomale J; Stuschke M
    Sci Rep; 2019 Feb; 9(1):1282. PubMed ID: 30718758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS; Zheng YL; Zhao J; Chun X
    Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
    Roesch A; Vultur A; Bogeski I; Wang H; Zimmermann KM; Speicher D; Körbel C; Laschke MW; Gimotty PA; Philipp SE; Krause E; Pätzold S; Villanueva J; Krepler C; Fukunaga-Kalabis M; Hoth M; Bastian BC; Vogt T; Herlyn M
    Cancer Cell; 2013 Jun; 23(6):811-25. PubMed ID: 23764003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
    Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
    Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
    Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
    J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing JARID1B suppresses oncogenicity, stemness and increases radiation sensitivity in human oral carcinoma.
    Lin CS; Lin YC; Adebayo BO; Wu A; Chen JH; Peng YJ; Cheng MF; Lee WH; Hsiao M; Chao TY; Yeh CT
    Cancer Lett; 2015 Nov; 368(1):36-45. PubMed ID: 26184998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
    Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
    Tian W; Sun Y; Cheng Y; Ma X; Du W; Shi W; Guo Q
    Thorac Cancer; 2021 Oct; 12(19):2551-2563. PubMed ID: 34469060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
    Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
    Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jumonji AT-rich interactive domain 1B overexpression is associated with the development and progression of glioma.
    Fang L; Zhao J; Wang D; Zhu L; Wang J; Jiang K
    Int J Mol Med; 2016 Jul; 38(1):172-82. PubMed ID: 27246838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.